Post highlights
- SiPore® technology took more than 15 years to develop, beginning in 2007 at Stockholm University under Prof. Tore Bengtsson.
- The technology was validated through multiple clinical studies before a single consumer product existed. The science came first.
- Glucose Stabilizer launched in 2024 as the first consumer product, designed to make SiPore® accessible as a daily dietary supplement.
- Carb Fence launched in 2026 as a medical food, delivering a higher SiPore® dose per sachet for use in more structured metabolic health contexts.
- Two products exist because the need for metabolic support is not one-size-fits-all. The technology is the same. The application is calibrated to what each person actually needs.
When people discover that SIGRID makes two products powered by the same technology, one of the first questions they ask is: why?
It is a fair question. If SiPore® is the active ingredient in both, what is the point of having two products?
The answer is not a marketing decision. It reflects something more fundamental about how metabolic support actually needs to work in the real world, and the journey it took to get there.
Where it started
In 2007, Prof. Tore Bengtsson and his team at Stockholm University began developing a technology with a specific goal in mind: to reduce the negative impact of modern meals by modulating digestion locally in the gut.
The premise was straightforward. Modern food is designed for speed, convenience, and palatability. It is absorbed very quickly. That speed is a significant part of what drives the post-meal spikes, energy crashes, and appetite dysregulation that characterise modern metabolic health.
Rather than trying to change what people eat, the question was whether it was possible to change how a meal is absorbed, at the level of digestion itself, without systemic intervention.
The answer was SiPore®.
Fifteen years of research before a product existed
What followed was more than a decade of work. Preclinical research between 2014 and 2020 confirmed the mechanism: SiPore® particles, precisely engineered with controlled pores, could temporarily entrap digestive enzymes in the small intestine, slowing the breakdown of carbohydrates and fats without blocking digestion entirely.
Early human trials established safety and tolerability. Clinical studies between 2021 and 2023 explored efficacy in obesity and prediabetes, showing meaningful improvements in HbA1c and a range of metabolic markers across multiple studies.
In 2025, the SHINE pivotal trial, a randomised, double-blind, placebo-controlled study with 252 participants over 12 weeks, confirmed safety and efficacy at the scale needed to support broad market access. SHINE was presented at the EASD Annual Meeting in Vienna. SiPore® patents were granted in the United States.
The science arrived first. The products followed. That order matters, and it is not how most supplement companies operate.
Why Glucose Stabilizer came first
In 2024, SIGRID launched Glucose Stabilizer, a dietary supplement in capsule form containing 0.375g of SiPore® per capsule.
The decision to launch a consumer supplement first was deliberate. The goal was to make SiPore® technology accessible to people who wanted everyday metabolic support, without requiring a healthcare provider relationship to access it.
Glucose Stabilizer is designed for consistent daily use. Four capsules with food across the day, supporting steadier post-meal responses as a sustainable habit. It is the entry point into the SiPore® ecosystem: flexible, accessible, and built for the long term.
For many people, it is exactly the right level of support. A consistent, gentle modulation of how meals are absorbed, day after day, that compounds over time into more stable metabolic patterns.
Less impact per meal. Stability over time.
Why Carb Fence needed to exist
The clinical research told a more nuanced story.
The SHINE trial used 9g of SiPore® per day across three doses, equivalent to three Carb Fence sachets. The outcomes observed at that dose level across weight, body composition, glucose markers, and lipid markers were consistent with earlier studies and established a strong evidence base for higher-dose SiPore® use in more structured metabolic health contexts.
For people with more significant metabolic challenges, those who experience larger post-meal responses, higher appetite variability, or who are working with a healthcare provider on a specific metabolic goal, a higher per-meal dose of SiPore® may provide more meaningful support than the consumer supplement alone.
That is what Carb Fence is designed for. At 3g of SiPore® per sachet, it delivers eight times the dose of a single Glucose Stabilizer capsule. The liquid format makes it convenient to take immediately before a meal. And as a medical food, it sits within a structured healthcare context where it can be used as part of a more comprehensive dietary management approach.
Carb Fence launched in 2026 as SIGRID's flagship HCP product, developed specifically for the practitioner channel.
The same technology, calibrated differently
Both products work by the same mechanism. SiPore® particles interact with digestive enzymes in the small intestine, temporarily reducing their activity and slowing the breakdown of carbohydrates and fats. Both are non-systemic. Both are gut-local. Both are naturally excreted.
What differs is the dose and the context of use.
Glucose Stabilizer is calibrated for the person who wants consistent, everyday support. Accessible, flexible, sustainable.
Carb Fence is calibrated for the person who needs stronger per-meal support, working within a more structured approach to metabolic health, ideally with healthcare provider guidance.
The existence of two products is not a duplication. It is a recognition that metabolic support needs are not one-size-fits-all. The right dose depends on the meal. The right product depends on the goal.
What this means in practice
For most people starting with SiPore® technology, Glucose Stabilizer is the natural beginning. It is available directly, requires no prescription or practitioner relationship, and is designed to be taken consistently over the long term.
For people who want to explore whether a higher dose of SiPore® might be appropriate for their circumstances, that conversation belongs with a healthcare provider, who can advise on whether Carb Fence is suitable and how to use it as part of a broader approach.
The one rule that applies to both is simple: one meal, one product. Never both at the same meal. Choose based on the meal, the goal, and the level of support that is appropriate.
Both products are most effective alongside balanced meals, regular movement, adequate sleep, and consistent lifestyle habits. Neither replaces those foundations. They work with them.
Less impact per meal. Stability over time.
-----
References
SHINE Pivotal Trial. Randomized, double-blind, placebo-controlled. n=252, 12 weeks. Presented at EASD Vienna 2025. Data on file, Sigrid Therapeutics.
SiPore® Technology Consumer Overview. Sigrid Therapeutics.
Sigrid Therapeutics Practitioner Sales Deck. March 2026.
